Gelonghui, April 8, 丨 Xiushentang (08200.HK) announced that on April 8, 2024, the Group acquired a total of 15 million shares of the target company (Clarity Medical Group Holdings Limited) at a total cost of about HK$8.95 million (not including transaction costs) through in-market transactions carried out on the Stock Exchange, which is equivalent to approximately HK$0.60 per share.

During the 12-month period prior to the date of the target company's acquisition, the Group acquired a total of 1.3 million shares of the target company at a total cost of approximately HK$923,900 (not including transaction costs).

Following the acquisition of the target company, the Group held a total of 16.3 million shares of the target company, which is equivalent to approximately 3.09% of the total issued share capital of the target company on the announcement date (calculated that 528,125,000 shares of the target company were issued on March 31, 2024, according to publicly available information).

The target company is an investment holding company. The target company and its subsidiaries are mainly engaged in providing private eye care services in Hong Kong. The directors have been actively seeking new investment opportunities to make full use of the Group's resources and promote the diversified development of its investment portfolio. The directors believe that the acquisition will expand the Group's investment portfolio. Since (i) the transaction in the acquisition was carried out on the Stock Exchange; (ii) the transaction price in the acquisition was based on the purchase or sale price reported by the Stock Exchange at the time the transaction was carried out; and (iii) it was anticipated that the acquisition would bring such benefits to the Group, the directors believed that the acquisition was carried out on normal commercial terms, fair and reasonable, and in line with the overall interests of the company and its shareholders.